February 23, 2004
Gilead Sciences to Present at 2004 BIO CEO & Investor Conference; Webcast Available Through Gilead Corporate Website
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 23, 2004--Gilead Sciences, Inc. (Nasdaq:GILD) announced today that members of the Company's management team will participate in the Biotechnology Industry Organization's 6th Annual BIO CEO & Investor Conference taking place in New York on February 24-25, 2004. These webcasts may be accessed via the company's corporate website at www.gilead.com.
John Martin, PhD, Gilead's President and Chief Executive Officer, will provide an overview of the company and an update on key business milestones for 2004 on Tuesday, February 24, 2004 at 11:30 a.m. Eastern Time. Then, on Wednesday, February 25th at 9:30 a.m. Eastern Time, Carol Brosgart MD, Vice President of Clinical Research, will participate on the panel "INFECTIOUS DISEASE: Hepatitis A, B & C: If the War Is Over, How Come We're Still Fighting?"
To access the live webcasts or the seven-day archive via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to the live presentations to ensure adequate time for any software download that may be necessary to view the webcasts.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide. The company has six marketed products and focuses its research and clinical programs on anti-infectives. Headquartered in Foster City, CA, Gilead has operations in the United States, Europe and Australia.
For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investor Relations)
SOURCE: Gilead Sciences, Inc.